logo-loader

Zynerba Pharmaceuticals boosts intellectual property portfolio with new patents for Zygel

Published: 11:53 03 Nov 2022 EDT

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) chairman and CEO Armando Anido tells Proactive's Stephen Gunnion that the company has expanded its intellectual property (IP) portfolio for Zygel, the first and only pharmaceutically-manufactured cannabidiol formulated as a permeation-enhanced clear gel, designed to provide controlled drug delivery into the bloodstream transdermally.

Following a new US patent for the treatment of Fragile X Syndrome, Anido says Zynerba has now also received a patent for the treatment of 22q11.2 deletion syndrome (22q).

The next steps are to file for a New Drug Application for Fragile X, while it meets the Food and Drug Administration's suggestions to get regulatory approval for 22q, he adds.

Coniagas Battery Metals secures new key ground with focus on...

Coniagas Battery Metals (TSX-V:COS) CEO Frank Basa joined Steve Darling from Proactive to announce the company's strategic acquisition of key ground near SOQUEM’s Cardinal Property, located 80 km southeast of Chibougamau, Quebec. This acquisition underscores Coniagas’ commitment to capitalizing...

50 minutes ago